Pegylated interferon α-2b

DRUG5 trials

Sponsors

University Hospital Schleswig-Holstein, Northwestern University, Amsterdam UMC, location VUmc, Huiqiang Huang, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Chronic Myeloid LeukemiaLymphomaLymphoma, B-CellMelanomaPolycythemia Vera

Phase 2

Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma

CompletedNCT00623402

University Hospital Schleswig-HolsteinMelanoma

Start: 2008-01-31Target: 55Updated: 2011-01-12

Nilotinib Plus Pegylated Interferon-α2b in CML

TerminatedNCT01866553

Amsterdam UMC, location VUmcChronic Myeloid Leukemia

Start: 2013-04-30End: 2016-05-01Updated: 2018-10-12

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

Huiqiang HuangLymphoma, B-Cell

Start: 2020-01-15End: 2023-01-16Target: 52Updated: 2022-04-07

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

RecruitingNCT05870475

Institute of Hematology & Blood Diseases Hospital, ChinaPolycythemia Vera

Start: 2023-06-30End: 2028-05-31Target: 94Updated: 2024-07-03

Unknown Phase

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

TerminatedNCT00724061

Northwestern UniversityLymphoma

Start: 2008-09-30End: 2011-12-31Updated: 2018-12-12

Related Papers

Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study

Blood2025-11-03

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

Blood2023-11-02

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.

2023-04-296 citations

Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Multicenter, Single-Arm, Phase II Study

Blood2021-11-05

Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).

2013-07-237 citations